Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer
| Autor: | Herrero, Cristina, de la Fuente, A., Casas-Arozamena, Carlos, Sebastian, V., Prieto, M., Arruebo, M., Abalo, Alicia, Colás Ortega, Eva, Moreno-Bueno, G., Gil-Moreno, Antonio, Vilar, A., Cueva, Juan, Abal Posada, Miguel, Muinelo-Romay, L., Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | Universidade de Santiago de Compostela. Departamento de Cirurxía e Especialidades Médico-Cirúrxicas, Instituto de Salud Carlos III, European Commission, Asociación Española Contra el Cáncer, UAM. Departamento de Bioquímica |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Cancer Research L1 Response to therapy Medicina Extracellular vesicles Article 03 medical and health sciences 0302 clinical medicine Endometrial cancer ANXA2 medicine Liquid biopsy EVs ExoGAG business.industry Cancer medicine.disease Technical performance 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research business Annexin A2 |
| Zdroj: | Minerva: Repositorio Institucional de la Universidad de Santiago de Compostela Universidad de Santiago de Compostela (USC) Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela instname Biblos-e Archivo. Repositorio Institucional de la UAM Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Digital.CSIC. Repositorio Institucional del CSIC Biblos-e Archivo: Repositorio Institucional de la UAM Universidad Autónoma de Madrid Cancers Volume 11 Issue 12 |
| Popis: | © 2019 by the authors. Tumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient´s outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-efficient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly efficient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analyses. This research was funded by Instituto de Salud Carlos III, grant PI17/01919, co-financed by the European Regional Development Fund (FEDER), and by Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Grupos Clínicos Coordinados 2018. Carolina Herrero is supported by a predoctoral i-PFIS fellowship from Instituto de Salud Carlos III (IFI17/00047); Laura Muinelo is supported by Asociación Española Contra el Cáncer (AECC). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|